Phase I Trial of Fenretinide Delivered Orally in a Novel Organized Lipid Complex in Patients with Relapsed/Refractory Neuroblastoma: A Report from the New Approaches to Neuroblastoma Therapy (NANT) Consortium

BACKGROUND: A phase I study was conducted to determine the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetics of fenretinide (4-HPR) delivered in an oral powderized lipid complex (LXS) in patients with relapsed/refractory neuroblastoma. PROCEDURE: 4-HPR/LXS powder (352 - 2...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Maurer, Barry J., Kang, Min H., Janeba, Jitka, Villablanca, Judith G., Groshen, Susan, Matthay, Katherine K., Sondel, Paul M., Maris, John M., Jackson, Hollie A., Goodarzian, Fariba, Shimada, Hiroyuki, Czarnecki, Scarlett, Hasenauer, Beth, Reynolds, C. Patrick, Marachelian, Araz
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2013
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4066886/
https://ncbi.nlm.nih.gov/pubmed/23813912
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.24643
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge